These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 29429897)

  • 1. Role of immunotherapy in bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
    Mukherjee N; Svatek RS; Mansour AM
    Urol Oncol; 2018 Mar; 36(3):103-108. PubMed ID: 29429897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
    Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
    Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
    Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ
    J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravesical bacillus Calmette-Guérin instillation in non-muscle-invasive bladder cancer: A review.
    Saluja M; Gilling P
    Int J Urol; 2018 Jan; 25(1):18-24. PubMed ID: 28741703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer.
    Steinberg GD; Shore ND; Redorta JP; Galsky MD; Bedke J; Ku JH; Kretkowski M; Hu H; Penkov K; Vermette JJ; Tarazi JC; Randall AE; Pierce KJ; Saltzstein D; Powles TB
    Future Oncol; 2024 May; 20(14):891-901. PubMed ID: 38189180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging treatments for bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer.
    Kim HS; Seo HK
    Investig Clin Urol; 2021 Jul; 62(4):361-377. PubMed ID: 34085791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bladder-preserving strategies for Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer; where are we and what will be expected?
    Sari Motlagh R; Pradere B; Mori K; Miura N; Abufaraj M; Shariat SF
    Curr Opin Urol; 2020 Jul; 30(4):584-593. PubMed ID: 32304379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravesical bacillus Calmette-Guerin immunotherapy after previous prostate radiotherapy for high-grade non-muscle-invasive bladder cancer.
    Rao MV; Ellimoottil C; Sondej T; Flanigan RC; Quek ML
    Urol Oncol; 2013 Aug; 31(6):857-61. PubMed ID: 21868262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
    Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
    J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What to do during Bacillus Calmette-Guérin shortage? Valid strategies based on evidence.
    Abufaraj M; Mostafid H; Shariat SF; Babjuk M
    Curr Opin Urol; 2018 Nov; 28(6):570-576. PubMed ID: 30138122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
    Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
    J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacillus Calmette-Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections.
    Larsen ES; Joensen UN; Poulsen AM; Goletti D; Johansen IS
    APMIS; 2020 Feb; 128(2):92-103. PubMed ID: 31755155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immuno-oncological therapeutic options in high-risk non-muscle invasive bladder cancer].
    Kramer MW; Gakis G
    Urologe A; 2020 Jul; 59(7):784-789. PubMed ID: 32468091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging Immunotherapy Options for bacillus Calmette-Guérin Unresponsive Nonmuscle Invasive Bladder Cancer.
    Meng MV; Gschwend JE; Shore N; Grossfeld GD; Mostafid H; Black PC
    J Urol; 2019 Dec; 202(6):1111-1119. PubMed ID: 31042108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.
    Bellmunt J; Powles T; Vogelzang NJ
    Cancer Treat Rev; 2017 Mar; 54():58-67. PubMed ID: 28214651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
    Lamm D; Brausi M; O'Donnell MA; Witjes JA
    Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic anti-CTLA-4 and intravesical Bacille-Calmette-Guerin therapy in non-muscle invasive bladder cancer: Is there a rationale of synergism?
    Fahmy O; Khairul-Asri MG; Stenzl A; Gakis G
    Med Hypotheses; 2016 Jul; 92():57-8. PubMed ID: 27241256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging role of checkpoint inhibition in localized bladder cancer.
    Singh P; Black P
    Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical and alternative bladder-preservation therapies in the management of non-muscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin.
    Steinberg RL; Thomas LJ; Nepple KG
    Urol Oncol; 2016 Jun; 34(6):279-89. PubMed ID: 26777259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The evolving role of PD-(L)1 inhibition.
    Bedke J; Black PC; Szabados B; Guerrero-Ramos F; Shariat SF; Xylinas E; Brinkmann J; Blake-Haskins JA; Cesari R; Redorta JP
    Urol Oncol; 2023 Dec; 41(12):461-475. PubMed ID: 37968169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.